Olanzapine for schizophrenia

Duggan, Lorna; Fenton, Mark; Dardennes, Roland; El‐Dosoky, Ahmed; Indran, Saroja K.

doi:10.1002/14651858.cd001359

Cited by 86 publications

(107 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Withdrawal rates in other long-term trials of atypicals can also be high. For example, dropout rates at 1 year are reported to be around 45-91% for olanzapine (Tran et al, 1999;Duggan et al, 2003); 44% for risperidone (Csernansky et al, 2002); 45% for amisulpride (Colonna et al, 2000) and 52-66% for haloperidol (Tran et al, 1999;Colonna et al, 2000;Csernansky et al, 2002). In another 28-week study of ziprasidone versus haloperidol in outpatients with stable schizophrenia, over 55% of patients failed to complete the study (Hirsch et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

Kasper¹,

Brecher

Fitton

et al. 2004

International Clinical Psychopharmacology

View full text Add to dashboard Cite

As schizophrenia is a chronic disorder, it is important that treatment be given over a long period of time to avoid relapse. Quetiapine, an atypical antipsychotic, has established efficacy and good tolerability in the short-term treatment of schizophrenia. This study investigated the long-term efficacy and safety of quetiapine in 674 patients with schizophrenia using combined data from the open-label extension phase of four Phase IIIa trials. The results showed that quetiapine, at a mean daily dose of 472.4 mg, provided progressive improvement and maintenance in the Brief Psychiatric Rating Scale total, positive- and negative-symptoms cluster, Clinical Global Impression Severity of Illness, and Scale for the Assessment of Negative Symptoms total scores over 208 weeks and beyond. Furthermore, quetiapine was well tolerated throughout the study period, with a low incidence of extrapyramidal symptom-related adverse events. In conclusion, quetiapine may be a suitable therapy in the long-term treatment of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

Kasper¹,

Brecher

Fitton

et al. 2004

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…However, such drugs may induce some side effects such as acute Parkinsonism, tardive dyskinesia and neuroleptic malignant syndrome. [1][2][3][4][5][6][7] Sexual dysfunction is often not specifi cally evaluated in clinical studies. When it affects patients on drug therapy, it affects their self-esteem, causes trouble for their sexual partners, interferes with their quality of life and compromises treatment compliance.…”

Section: Introductionmentioning

confidence: 99%

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

2006

View full text Add to dashboard Cite

INTRODUCTION: Sexual dysfunction frequently occurs in patients with schizophrenia under antipsychotic therapy, and the presence of sexual side effects may affect compliance. The aim of this study was to review and describe clinical findings relating to the appropriate management of such dysfunctions. MATERIAL AND METHODS: The research was carried out through Medline (from 1966 to March 2005), PsycInfo (from 1974 to March 2005), and Cochrane Library (from 1965 to March 2005) and included any kind of study, from case reports to randomized trials. RESULTS: The most common sexual dysfunctions found in the literature were libido decrease, difficulties in achieving and maintaining erection, ejaculatory dysfunction, orgasmic dysfunction, and menstrual irregularities. Thirteen papers were found: eight of them were open-label studies, four were descriptions of cases, and only one was a randomized clinical trial. All of them were short-term and had small sample sizes. The agents used were: bromocriptine, cabergoline, cyproheptadine, amantadine, shakuyaku-kanzo-to, sildenafil and selegiline. DISCUSSION: There was no evidence that those agents had proper efficacy in treating the antipsychotic-induced sexual dysfunction. An algorithm for managing sexual dysfunction induced by antipsychotics is suggested as a support for clinical decisions. Since the outcome from schizophrenia treatment is strongly related to compliance with the antipsychotics, prevention of sexual dysfunction is better than its treatment, since there is a scarcity of data available regarding the efficacy of intervention to deal with these problems.

show abstract

“…It showed a higher incidence of EPS than did olanzapine (Duggan et al, 2000). In addition, anticholinergic symptoms, such as dizziness and dry mouth, were found to be more common in association with olanzapine treatment than with risperidone treatment (Duggan et al, 2000). Lavalaye et al (2001) compared the mAChR occupancy by olanzapine and risperidone in schizophrenia patients using [ 123 I]IDEX SPECT.…”

Section: Pharmacologymentioning

confidence: 99%